You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The partners will develop an amyloid β 42/40 ratio assay to identify patients who may benefit from treatment with Janssen's drug called atabecestat.
Sebia and Janssen Biotech collaborated on the development of the test, which is for assessing patients treated with Darzalex.
Genomic Health will test samples from Janssen prostate cancer drug studies to examine whether its test can predict patient outcomes.
The panel, developed by collaborator Janssen, is expected to improve detection of influenza and respiratory syncytial virus.
The purchase from Janssen of a liquid biopsy test for circulating tumor cells marks Menarini-Silicon's entry into the US diagnostics market.
The test may mitigate potential interference during immunofixation tests that measure a patient’s response to a multiple myeloma therapy.
The firm also announced that it plans to expand its RAS biomarker testing collaboration with Amgen in Europe.
Cellsearch is the only FDA-cleared circulating tumor cell test and is used to help manage patients with metastatic breast, prostate, and colorectal cancers.